Search
+
    SEARCHED FOR:

    ZYDUS CADILA

    Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%

    The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.

    When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%

    Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.

    Right pricing to hold the key for Zydus Cadila's vaccine launch

    Zydus Cadila has the drug regulator's emergency use authorisation to administer its Covid vaccine, ZyCoV-D, in children aged 12-18 years. As Covaxin is set to become available for the same age group as well, the bargaining position of the government will improve, as negotiations are underway with Zydus regarding the price of the vaccine.

    Government lab releases first batch of Zydus Cadila's covid vaccine ZyCoV-D

    Needle-free ZyCoV-D, manufactured by Ahmedabad-based Zydus Cadila, is the first Covid-19 vaccine approved for the 12 to 18 years age group in India.

    Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug

    Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing.

    Zydus Cadila, Taiwan's TLC ink pact to market black fungus drug in India

    The Central Drugs Standard Control Organization has approved the new drug application (NDA) of TLC for Amphotericin B Liposome for Injection 50mg for immediate importation as per approved usage and indication, Zydus Cadila said.

    The Economic Times
    BACK TO TOP